1. Lymphomas Expressing ALK Fusion Protein(s) Other Than NPM-ALK
by Brunangelo Falini, Karen Pulford, Alessandra Pucciarini, Antonino Carbone, Chris De Wolf-Peeters, Jacqueline Cordell, Marco Fizzotti, Antonella Santucci, Pier-Giuseppe Pelicci, Stefano Pileri, Elias Campo, German Ott, Georges Delsol, and David Y. Mason
Blood
Volume 94(10):
November 15, 1999
©1999 by American Society of Hematology

2. Immunostaining of an ALK-positive lymphoma bearing the t(2;5) translocation (top left and right).
Immunostaining of an ALK-positive lymphoma bearing the t(2;5) translocation (top left and right). (Top left) Immunostaining for ALK protein. Tumor cells (arrow) show strong cytoplasmic and nuclear ALK expression. Residual lymphoid tissue is ALK-negative (original magnification × 800). (Top right) Tumor cells (arrow) show cytoplasmic and nuclear positivity for the N-terminus of NPM (N-NPM). Cytoplasmic positivity reflects immunostaining of the NPM moiety of the NPM-ALK fusion protein. Normal residual lymphoid cells (arrowhead) show wild-type nucleus-restricted NPM staining (original magnification × 800). In contrast, immunostaining for the C-terminus of NPM showed a nucleus-restricted expression of the protein (not shown). (Bottom left and right) An example of ALK-positive lymphoma expressing variant ALK fusion protein. (Bottom left) Positivity for the ALK protein is restricted to the cytoplasm of the large anaplastic tumor cells (arrowhead; original magnification × 1,000; right). The N-terminus of NPM (N-NPM) shows nucleus-restricted expression both in tumor cells (arrowhead) and in a normal endothelial cell (arrow), reflecting immunostaining of wild-type NPM (original magnification × 1,000). An identical staining pattern (not shown) was observed for the C-terminus of NPM. (APAAP immunostaining on lymph node paraffin sections; hematoxylin counterstaining.)‏
Brunangelo Falini et al. Blood 1999;94:
©1999 by American Society of Hematology

3. Schematic illustration of the staining patterns for ALK and the N- and C-terminal portions of NPM in lymphomas carrying NPM-ALK or variant ALK fusion protein(s).
Schematic illustration of the staining patterns for ALK and the N- and C-terminal portions of NPM in lymphomas carrying NPM-ALK or variant ALK fusion protein(s). Further details of the reactivity of the anti-NPM monoclonal antibodies have been published elsewhere.31
Brunangelo Falini et al. Blood 1999;94:
©1999 by American Society of Hematology

4. Overall survival of ALK-positive lymphomas expressing NPM-ALK (n = 44), variant ALK fusion protein(s) (“x-ALK”) (n = 15), and ALK-negative anaplastic large-cell lymphomas (n = 25).
Overall survival of ALK-positive lymphomas expressing NPM-ALK (n = 44), variant ALK fusion protein(s) (“x-ALK”) (n = 15), and ALK-negative anaplastic large-cell lymphomas (n = 25).
Brunangelo Falini et al. Blood 1999;94:
©1999 by American Society of Hematology